states, territories, tribes and tribal organizations, area agencies on aging and service providers in delivering services under the Act. We also seek feedback on how OAA programs can advance equity, in alignment with Executive Order 13985 *Advancing Racial Equity and Support for Underserved Communities Through the Federal Government.* In this regard, please keep in mind the following:

- All submissions will be considered and reviewed by ACL.
- ACL seeks recommendations to address practical matters regarding regulations to implement the Older Americans Act, as reauthorized in 2020. (We may not be able to include all recommendations.)
- If respondents have multiple recommendations, respondents may make multiple recommendations in the same submission.

Submission Questions

1. State the regulation for which the comment applies:
a. 45 CFR part 1321—Grants to State and Community Programs on Aging;
b. 45 CFR part 1322—Grants to Indian Tribes for Support and Nutrition Services;
c. 45 CFR part 1323—Grants for Supportive and Nutritional Services to Older Hawaiian Natives; or
d. 45 CFR part 1324 Allotments for Vulnerable Elder Rights Protection Activities, including Subpart A—State Long-Term Care Ombudsman Program.
2. State the citation to which the comment applies, if applicable (for example, ''45 CFR part 1321.1'').
3. State the nature of the comment:
a. Deletion.
b. Addition.
c. Change.
4. Provide detail on the reason for ACL to consider the comment for potential inclusion in a revision of Older Americans Act regulations.
5. Provide detail on any benefits, including how equity will be advanced, and/or barriers that might result from incorporating the recommendation in a revision of Older Americans Act regulations.

Please Note: This RFI is being issued for information and planning purposes only. It should not be construed as a solicitation or an obligation on the part of the federal government or the Administration for Community Living (ACL). ACL does not intend to issue any grant or contract awards based on responses to this invitation, or to otherwise pay for the preparation of any information submitted or for the government's use of such information. ACL is not authorized to receive personally identifiable information (PII) through this RFI other than the contact information of the person submitting the information. Please do not include any PII in your submission. For example, do not include names, addresses, phone or Social Security numbers of any individuals. We will redact responses that contain PII.

How the Information Will Be Used

ACL is planning to update regulations for programs authorized under Titles III, VI, and VII of the Older Americans Act. The information gathered through this RFI will be used to inform ACL's approach to updating these regulations.

Background

Congress passed the Older Americans Act (OAA) in 1965 in response to concern by policymakers about a lack of community social services for older persons. The original legislation established authority for grants to states for community planning and social services, research and development projects, and personnel training in the field of aging. The law also established the Administration on Aging (AoA) to administer the newly created grant programs and to serve as the federal focal point on matters concerning older persons.

Although older individuals may receive services under many other federal programs, today the OAA is considered to be a major vehicle for the organization and delivery of social and nutrition services to this group and their caregivers. It authorizes a wide array of service programs through a national network of 56 state agencies on aging, 618 area agencies on aging, nearly 20,000 service providers, 281 Tribal organizations, representing 400 Tribes, and 1 Native Hawaiian organization. The OAA was most recently reauthorized on March 25, 2020.

Dated: May 2, 2022.

Alison Barkoff,

Acting Assistant Secretary for Aging and Administrator, Administration for Community Living.

Dated: May 2, 2022.

Xavier Becerra,

Secretary, Department of Health and Human Services.

[FR Doc. 2022–09713 Filed 5–5–22; 8:45 am]

BILLING CODE 4154–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA–1998–P–0074]

Grated Parmesan Cheese Deviating From Identity Standard; Amendment of Temporary Marketing Permit

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA or we) is amending the temporary permit issued to Kraft Foods Inc. to market test a product designated as ''100% Grated Parmesan Cheese'' that deviates from the standards of identity for parmesan cheese and grated cheeses. Kraft Foods Inc.'s temporary permit is amended to identify Lactalis Heritage Dairy, Inc. (LHD) as the permit holder. This amendment will allow the permit holder to continue to test market the product and collect data on consumer acceptance.

FOR FURTHER INFORMATION CONTACT: Marjan Morravej, Office of Nutrition and Food Labeling (HFS–820), Center for Food Safety and Applied Nutrition, Food and Drug Administration, 5001 Campus Dr., College Park, MD 20740, 240–402–2371; or Alexandra Jurewitz, Office of Regulations and Policy (HFS–024), Center for Food Safety and Applied Nutrition, Food and Drug Administration, 5001 Campus Dr., College Park, MD 20740, 240–402–2378.

SUPPLEMENTARY INFORMATION: In the **Federal Register** of April 6, 1999 (64 FR 16743), we issued a notice announcing that we had issued a temporary permit to Kraft Foods Inc. (now a part of Kraft Heinz, 200 East Randolph St., Suite 7600, Chicago, IL 60601), to market test a product identified as ''100% Grated Parmesan Cheese.'' We issued the permit to facilitate market testing of a product that deviates from the requirements of the standard of identity for parmesan cheese (21 CFR 133.165) and grated cheeses (21 CFR 133.146) in that the product is formulated by using a different enzyme technology that fully cures the cheese in 6 months rather than 10 months.

In the **Federal Register** of December 29, 2000 (65 FR 83040), we issued a notice announcing that we were extending the temporary market permit issued to Kraft Foods Inc. The extension allows the applicant to continue to measure consumer acceptance of the product and assess the commercial feasibility of the product, in support of

a petition to amend the standard of identity for parmesan cheese. The new expiration date of the permit will be either the effective date of a final rule amending the standard of identity for parmesan cheese that may result from the petition or 30 days after denial of the petition.

In 2011, Kraft Foods Inc. spun off its North American grocery business to a new company called Kraft Foods Group. In 2015, Kraft Foods Group and H.J. Heinz Company merged to become Kraft Heinz. In September 2020, Kraft Heinz entered into an agreement to sell its natural, grated, cultured, and specialty cheese businesses in the United States, including its Kraft parmesan cheese business, to B.S.A. S.A., the parent company of the Lactalis Group (Lactalis) and its subsidiary, LHD. As of November 29, 2021, LHD has assumed responsibility for production and sale of all parmesan cheese subject to the temporary permit.

Under our regulations at 21 CFR 130.17(f), we are modifying the temporary permit issued to Kraft Foods Inc. for ''100% Grated Parmesan Cheese'' to identify LHD, 540 West Madison St., Suite 300, Chicago, IL 60661, as the permit holder. All other conditions and terms of this permit remain the same.

Dated: April 29, 2022.

Lauren K. Roth,

Associate Commissioner for Policy.

[FR Doc. 2022–09750 Filed 5–5–22; 8:45 am]

BILLING CODE 4164–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA–2007–D–0369]

Product-Specific Guidance for Testosterone; Revised Draft Guidance for Industry; Availability

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of availability.

SUMMARY: The Food and Drug Administration (FDA or Agency) is announcing the availability of a revised draft guidance for industry entitled ''Draft Guidance for Testosterone.'' The revised draft guidance, when finalized, will provide product-specific recommendations on, among other things, the information and data needed to demonstrate bioequivalence (BE) to support abbreviated new drug applications (ANDAs) for testosterone pellet.

DATES: Submit either electronic or written comments on the draft guidance by July 5, 2022 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance.

ADDRESSES: You may submit comments on any guidance at any time as follows:

Electronic Submissions

Submit electronic comments in the following way:

- *Federal eRulemaking Portal: https://www.regulations.gov.* Follow the instructions for submitting comments. Comments submitted electronically, including attachments, to *https://www.regulations.gov* will be posted to the docket unchanged. Because your comment will be made public, you are solely responsible for ensuring that your comment does not include any confidential information that you or a third party may not wish to be posted, such as medical information, your or anyone else's Social Security number, or confidential business information, such as a manufacturing process. Please note that if you include your name, contact information, or other information that identifies you in the body of your comments, that information will be posted on *https://www.regulations.gov.*
- If you want to submit a comment with confidential information that you do not wish to be made available to the public, submit the comment as a written/paper submission and in the manner detailed (see ''Written/Paper Submissions'' and ''Instructions'').

Written/Paper Submissions

Submit written/paper submissions as follows:

- *Mail/Hand Delivery/Courier (for written/paper submissions):* Dockets Management Staff (HFA–305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
- For written/paper comments submitted to the Dockets Management Staff, FDA will post your comment, as well as any attachments, except for information submitted, marked and identified, as confidential, if submitted as detailed in ''Instructions.''

Instructions: All submissions received must include the Docket No. FDA–2007–D–0369 for ''Draft Guidance for Testosterone.'' Received comments will be placed in the docket and, except for those submitted as ''Confidential Submissions,'' publicly viewable at *https://www.regulations.gov* or at the Dockets Management Staff between 9 a.m. and 4 p.m., Monday through Friday, 240–402–7500.

- Confidential Submissions—To submit a comment with confidential information that you do not wish to be made publicly available, submit your comments only as a written/paper submission. You should submit two copies total. One copy will include the information you claim to be confidential with a heading or cover note that states ''THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' The Agency will review this copy, including the claimed confidential information, in its consideration of comments. The second copy, which will have the claimed confidential information redacted/blacked out, will be available for public viewing and posted on *https://www.regulations.gov.* Submit both copies to the Dockets Management Staff. If you do not wish your name and contact information to be made publicly available, you can provide this information on the cover sheet and not in the body of your comments and you must identify this information as ''confidential.'' Any information marked as ''confidential'' will not be disclosed except in accordance with 21 CFR 10.20 and other applicable disclosure law. For more information about FDA's posting of comments to public dockets, see 80 FR 56469, September 18, 2015, or access the information at: *https://www.govinfo.gov/content/pkg/FR-2015-09-18/pdf/2015-23389.pdf.*

Docket: For access to the docket to read background documents or the electronic and written/paper comments received, go to *https://www.regulations.gov* and insert the docket number, found in brackets in the heading of this document, into the ''Search'' box and follow the prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852, 240–402–7500.

You may submit comments on any guidance at any time (see 21 CFR 10.115(g)(5)).

Submit written requests for single copies of the draft guidance to the Division of Drug Information, Center for Drug Evaluation and Research, Food and Drug Administration, 10001 New Hampshire Ave., Hillandale Building, 4th Floor, Silver Spring, MD 20993–0002. Send one self-addressed adhesive label to assist that office in processing your requests. See the **SUPPLEMENTARY INFORMATION** section for electronic access to the draft guidance document.

FOR FURTHER INFORMATION CONTACT: Christine Le, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 75, Rm. 4714, Silver Spring, MD 20993–0002, 301–796–2398, *PSG-Questions@fda.hhs.gov.*

SUPPLEMENTARY INFORMATION: